Indeed Joe. You'd have to think the IMM meets all of Merck's/Rob Davis' acquisition criteria: NSCLC about to enter phase 3 (not to mention HNSCC results this year); Efti offsetting Keytruda's patent expiration in 2028; and most importantly, in his US$1-15 billion acquisition price target.
Media, page-606
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.015(3.66%) |
Mkt cap ! $505.2M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 44.0¢ | 39.5¢ | $3.455M | 8.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 81510 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
43.0¢ |
Change
0.015 ( 4.44 %) |
||||
| Open | High | Low | Volume | ||
| 40.5¢ | 43.8¢ | 39.5¢ | 1912918 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| IMM (ASX) Chart |